Resumo

AVILA PORTILLO, Luz Mabel et al. Effects of the use of granulocyte colony stimulating factor for obtaining stem cells in a group of patients with chronic occlusive arterial disease. Rev. colomb. cienc. quim. farm. [online]. 2010, vol.39, n.2, pp.122-131. ISSN 0034-7418.

The analyzed aspects such as efficacy and safety are important in the use of Granulocyte Colony Stimulating Factor in patients with chronic occlusive arterial disease were analyzed data from the cohort of patients with eaoc that regularly attended the Clinic for Vascular Surgery of the Hospital Militar Central in Bogotá. The protocol for CD34+ cell mobilization into peripheral blood involved the use of FEC - Grh at a dose of 600 mg/day administered subcutaneously (Filgrastim G - CSF 300 µg Roche®) divided into two daily doses, continuously for five days. By comparing the values from blood counts performed before and after mobilization showed increased significant number of leukocytes as well as proportion of neutrophils and basophiles, whereas proportions of monocytes, eosinophils and lymphocytes decreased significantly. About the CD34+ cell behavior, it's not shown significant difference between the behaviors of CD34+ with age, neither the IMC. The analyzed done on the weight and CD34+ levels was observed that patients achieved a good response with a weight of 59.7 kg while 68.1 kg patients with regular response.

Palavras-chave : filgrastim; hematopoietic cells mobilization.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )